Related Experiment Video
Updated: Jun 23, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Advances in the pathogenesis and treatment of polycystic kidney disease
Vishal Patel1, Renuka Chowdhury, Peter Igarashi
1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Purpose Of Review:
Polycystic kidney disease (PKD) is the most common genetic cause of chronic renal failure. Mouse models of PKD, especially those with mutations in genes that are orthologous to human disease genes, have provided insights into the pathogenesis of cyst formation and advanced the preclinical testing of new drugs.
Recent Findings:
PKD is a ciliopathy that arises from abnormalities in the primary cilium, a sensory organelle present on the surface of most cells. The primary cilium is required for the maintenance of planar cell polarity, which regulates tubular diameter. Acute kidney injury stimulates cell proliferation and promotes cyst formation in a mouse model of PKD. Studies of signaling pathways that are perturbed in PKD have identified new potential therapeutic targets. Drugs that have shown beneficial effects in orthologous animal models of PKD include tolvaptan, octreotide, src inhibitors, CFTR inhibitors, pioglitazone, etanercept, and triptolide.
Summary:
Abnormalities in the primary cilium perturb signaling pathways that regulate renal epithelial cell growth and differentiation and lead to the formation of kidney cysts. Acute kidney injury promotes cyst formation and may underlie the variability in disease progression that is observed in affected individuals. Several promising new therapeutic agents that have been validated in orthologous animal models have entered clinical trials in humans.
Insights
Polycystic kidney disease (PKD) stems from primary cilium defects, impacting kidney cell growth and leading to cyst formation. Promising therapies targeting these pathways are now in human clinical trials.
Area of Science:
- Nephrology
- Genetics
- Cell Biology
Background:
- Polycystic kidney disease (PKD) is the leading genetic cause of chronic kidney failure.
- Mouse models are crucial for understanding PKD pathogenesis and testing therapeutics.
Purpose of the Study:
- To review current understanding of PKD pathogenesis.
- To highlight therapeutic targets and agents validated in preclinical models.
Main Methods:
- Review of literature on PKD mouse models and ciliopathies.
- Analysis of signaling pathways implicated in cystogenesis.
- Summary of preclinical drug efficacy data.
Main Results:
- PKD is a ciliopathy linked to primary cilium dysfunction and altered planar cell polarity.
- Acute kidney injury exacerbates cyst formation in PKD models.
- Several drugs, including tolvaptan and src inhibitors, show promise in animal models.
Conclusions:
- Primary cilium abnormalities disrupt signaling, causing renal cyst formation.
- Acute kidney injury may influence PKD progression variability.
- Therapeutic agents validated in PKD models are advancing to human clinical trials.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Diabetic Nephropathy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease IV: Nursing Management
Nephrons

